Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.61 |
| ▸ | G6PD | P11413 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | PHGDH | O43175 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396870 | 0.83 | ALDH1A1 (0.80) | KDM4EALDH1A1MEN1KMT2AGFER | |
| SCHEMBL3036591 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1MEN1KMT2AG6PD | |
| SCHEMBL17131893 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1MEN1KMT2AG6PD | |
| SCHEMBL31358765 | 0.76 | MEN1 (1.00) | KDM4EALDH1A1MEN1KMT2AG6PD | |
| SCHEMBL12177745 | 0.76 | ALDH1A1 (0.69) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL18891690 | 0.75 | ALDH1A1 (0.60) | KDM4EALDH1A1MEN1KMT2AG6PD | |
| SCHEMBL6737754 | 0.75 | KDM4E (0.59) | KDM4EALDH1A1MEN1KMT2AG6PD | |
| SCHEMBL3366641 | 0.74 | MEN1 (0.79) | KDM4EALDH1A1MEN1KMT2AG6PD | |
| SCHEMBL3366643 | 0.74 | MEN1 (0.79) | KDM4EALDH1A1MEN1KMT2AG6PD | |
| SCHEMBL398700 | 0.74 | ALDH1A1 (0.67) | KDM4EALDH1A1LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005530823-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-20050215553-A1 | Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-09-29 | — | — | US | claimed |
| EP-1515953-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 2005-03-23 | — | — | EP | claimed |
| WO-2003106431-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | AVENTIS PHARMA S.A. (FR) | 2003-12-24 | — | — | WO | claimed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003106431-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | AVENTIS PHARMA S.A. (FR) | 2003-12-24 | — | — | WO | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-1998053790-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF VASCULAR ENDOTHELIAL GROWTH FACTOR TO ITS RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | KDM4E 2375/4885ALDH1A1 2602/4885MEN1 2267/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | KDM4E 1552/4885ALDH1A1 2424/4885MEN1 4108/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | KDM4E 317/4885ALDH1A1 3670/4885MEN1 1913/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | KDM4E 1909/4885ALDH1A1 1723/4885MEN1 2413/4885 |
| US-20050215553-A1 | Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation | HK1, ACE, CTSZ | KDM4E 2325/4885ALDH1A1 448/4885MEN1 1759/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | KDM4E 1552/4885ALDH1A1 2424/4885MEN1 4108/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | KDM4E 1909/4885ALDH1A1 1723/4885MEN1 2413/4885 |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K1, MAP3K15 | KDM4E 710/4885ALDH1A1 3566/4885MEN1 1149/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | KDM4E 317/4885ALDH1A1 3670/4885MEN1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.